C. Huang, Y. Wang, X. Li, L. Ren, J. Zhao et al., Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet, vol.395, pp.497-506, 2020.

W. Guan, Z. Ni, Y. Hu, W. Liang, C. Ou et al., Clinical characteristics of coronavirus disease 2019 in China, China Medical Treatment Expert Group for Covid, vol.382, pp.1708-1720, 2020.

P. Zhou, X. L. Yang, X. G. Wang, B. Hu, L. Zhang et al., A pneumonia outbreak associated with a new coronavirus of probable bat origin, Nature, vol.579, pp.270-273, 2020.

G. Grasselli, A. Zangrillo, A. Zanella, M. Antonelli, L. Cabrini et al., Baseline characteristics and outcomes of 1591 patients infected with SARS-CoV-2 admitted to ICUs of the Lombardy Region, COVID-19 Lombardy ICU Network, vol.323, pp.1574-1581, 2020.

X. Zhao, B. Zhang, P. Li, C. Ma, J. Gu et al., Incidence, clinical characteristics and prognostic factor of patients with COVID-19: a systematic review and meta-analysis, 2020.

A. Simonnet, M. Chetboun, J. Poissy, V. Raverdy, J. Noulette et al., High prevalence of obesity in severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) requiring invasive mechanical ventilation, Obesity, 2020.

B. Cao, Y. Wang, D. Wen, W. Liu, J. Wang et al., A trial of lopinavir-ritonavir in adults hospitalized with severe Covid-19, N. Engl. J. Med, vol.382, pp.1787-1799, 2020.

A. K. Singh, A. Singh, A. Shaikh, R. Singh, and A. Misra, Chloroquine and hydroxychloroquine in the treatment of COVID-19 with or without diabetes: a systematic search and a narrative review with a special reference to India and other developing countries, Diabetes Metab. Syndr, vol.14, pp.241-246, 2020.

D. Belhadi, N. Peiffer-smadja, F. Lescure, Y. Yazdanpanah, F. Mentré et al., A brief review of antiviral drugs evaluated in registered clinical trials for COVID-19, 2020.

. Med, , 2020.

P. Gautret, J. C. Lagier, P. Parola, V. T. Hoang, L. Meddeb et al., Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial, Int. J. Antimicrob. Agents, 2020.
URL : https://hal.archives-ouvertes.fr/hal-02525126

Y. Zhou, B. Fu, X. Zheng, D. Wang, C. Zhao et al., Pathogenic T cells and inflammatory monocytes incite inflammatory storm in severe COVID-19 patients, Natl. Sci. Rev, 2020.

Z. Xu, L. Shi, Y. Wang, J. Zhang, L. Huang et al., Pathological findings of COVID-19 associated with acute respiratory distress syndrome, Lancet Respir. Med, vol.8, pp.420-422, 2020.

W. Wang, J. He, P. Lie, I. Huang, S. Wu et al., The definition and risks of cytokine release syndrome-like in 11 COVID-19-infected pneumonia critically ill patients: disease characteristics and retrospective analysis, 2020.

C. Qin, L. Zhou, Z. Hu, S. Zhang, S. Yang et al., Dysregulation of immune response in patients with COVID-19 in Wuhan, China. Clin. Infect. Dis.-ciaa248, 2020.

B. Diao, C. Wang, Y. Tan, X. Chen, Y. Liu et al., Reduction and functional exhaustion of T cells in patients with coronavirus disease 2019 (COVID-19), Front Immunol, vol.11, p.827, 2020.

Y. Zhou, B. Fu, X. Zheng, D. Wang, C. Zhao et al., Aberrant pathogenic GM-CSF + T cells and inflammatory CD14 + CD16 + monocytes in severe pulmonary syndrome patients of a new coronavirus, 2020.

M. Liao, Y. Liu, J. Yuan, Y. Wen, G. Xu et al., Single-cell landscape of bronchoalveolar immune cells in patients with COVID-19, Nat. Med, 2020.

Z. Zhou, L. Ren, L. Zhang, J. Zhong, Y. Xiao et al., Heightened innate immune responses in the respiratory tract of COVID-19 patients, Cell Host Microbe, 2020.

C. Wu, X. Chen, Y. Cai, J. Xia, X. Zhou et al., Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China, JAMA Intern. Med, vol.13, 2020.

B. Zhou, J. She, Y. Wang, and X. Ma, Utility of ferritin, procalcitonin, and C-reactive protein in severe patients with 2019 novel coronavirus disease, 2020.

X. Luo, W. Zhou, X. Yan, T. Guo, B. Wang et al., Prognostic value of C-reactive protein in patients with COVID-19, 2020.

T. Liu, J. Zhang, Y. Yang, H. Ma, Z. Li et al., The potential role of IL-6 in monitoring severe case of coronavirus disease, 2019.

F. Zhou, T. Yu, R. Du, G. Fan, Y. Liu et al., Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study, Lancet, vol.395, pp.1054-1062, 2020.

Y. Wang, W. Jiang, Q. He, C. Wang, B. Wang et al., Early, low-dose and short-term application of corticosteroid treatment in patients with severe COVID-19 pneumonia: single-center experience from Wuhan, 2020.

X. Lu, T. Chen, Y. Wang, J. Wang, B. Zhang et al., Adjuvant corticosteroid therapy for critically ill patients with COVID-19, 2020.

L. J. Stockman, R. Bellamy, and P. Garner, SARS: systematic review of treatment effects, PLoS Med, vol.3, p.343, 2006.

Y. M. Arabi, Y. Mandourah, F. Al-hameed, A. A. Sindi, G. A. Almekhlafi et al., Corticosteroid therapy for critically ill patients with Middle East respiratory syndrome, Saudi Critical Care Trial Group, vol.197, pp.757-767, 2018.

, Clinical management of severe acute respiratory infection when COVID-19 is suspected, infection-is-suspected, WHO, 2020.

K. H. Walker and J. C. Pearson, Brigham and Women's Hospital COVID-19 clinical guidelines, 2020.

, Nonsteroidal anti-inflammatory drugs (NSAIDs) and serious infectious complications -Information Point, 2019.

H. Momattin, K. Mohammed, A. Zumla, Z. A. Memish, A. et al., Therapeutic options for Middle East respiratory syndrome coronavirus (MERS-CoV)-possible lessons from a systematic review of SARS-CoV therapy, Int. J. Infect. Dis, vol.17, pp.792-798, 2013.

Q. Liu, Y. Zhou, Y. , and Z. , The cytokine storm of severe influenza and development of immunomodulatory therapy, Cell. Mol. Immunol, vol.13, pp.3-10, 2016.

A. Shimabukuro-vornhagen, P. Gö-del, M. Subklewe, H. J. Stemmler, H. A. Schlö-ßer et al., Cytokine release syndrome, J. Immunother. Cancer, vol.6, p.56, 2018.

J. M. Michot, L. Albiges, N. Chaput, V. Saada, F. Pommeret et al., Tocilizumab, an anti-IL6 receptor antibody, to treat Covid-19-related respiratory failure: a case report, Ann. Oncol, 2020.

X. Xu, M. Han, T. Li, W. Sun, D. Wang et al., Effective treatment of severe COVID-19 patients with Tocilizumab, Proc Natl Acad Sci, 2020.

G. A. Yanik, V. T. Ho, J. E. Levine, E. S. White, T. Braun et al., The impact of soluble tumor necrosis factor receptor etanercept on the treatment of idiopathic pneumonia syndrome after allogeneic hematopoietic stem cell transplantation, Blood, vol.112, pp.3073-3081, 2008.

, Roivant announces development of anti-GM-CSF monoclonal antibody to prevent and treat acute respiratory distress syndrome (ARDS) in patients with COVID-19, Roivant Sciences, 2020.

P. Richardson, I. Griffin, C. Tucker, D. Smith, O. Oechsle et al., Baricitinib as potential treatment for 2019-nCoV acute respiratory disease, Lancet, vol.395, pp.30-31, 2020.

D. Wu, Y. , and X. O. , TH17 responses in cytokine storm of COVID-19: an emerging target of JAK2 inhibitor Fedratinib, J. Microbiol. Immunol. Infect, 2020.

J. Bayry, V. S. Negi, and S. V. Kaveri, Intravenous immunoglobulin therapy in rheumatic diseases, Nat. Rev. Rheumatol, vol.7, pp.349-359, 2011.
URL : https://hal.archives-ouvertes.fr/inserm-02455562

E. E. Perez, J. S. Orange, F. Bonilla, J. Chinen, I. K. Chinn et al., Update on the use of immunoglobulin in human disease: A review of evidence, J. Allergy Clin. Immunol, vol.139, issue.3S, pp.1-46, 2017.

W. Cao, X. Liu, T. Bai, H. Fan, K. Hong et al., High-dose intravenous immunoglobulin as a therapeutic option for deteriorating patients with coronavirus disease 2019, Open Forum Infect. Dis, vol.7, p.102, 2020.

Z. Shao, . Sr, Y. Feng, L. Zhong, Q. Xie et al., Clinical efficacy of intravenous immunoglobulin therapy in critical patients with COVID-19: a multicenter retrospective cohort study, 2020.

Y. Xie, S. Cao, Q. Li, E. Chen, H. Dong et al., Effect of regular intravenous immunoglobulin therapy on prognosis of severe pneumonia in patients with COVID-19, J. Infect. Published, 2020.

I. Schwab and F. Nimmerjahn, Intravenous immunoglobulin therapy: how does IgG modulate the immune system?, Nat. Rev. Immunol, vol.13, pp.176-189, 2013.

C. Galeotti, S. V. Kaveri, and J. Bayry, IVIG-mediated effector functions in autoimmune and inflammatory diseases, Int. Immunol, vol.29, pp.491-498, 2017.
URL : https://hal.archives-ouvertes.fr/hal-01723555

J. Bayry, S. Lacroix-desmazes, M. D. Kazatchkine, and S. V. Kaveri, Intravenous immunoglobulin for infectious diseases: back to the pre-antibiotic and passive prophylaxis era?, Trends Pharmacol. Sci, vol.25, pp.306-310, 2004.

B. Shopsin, S. V. Kaveri, and J. Bayry, Tackling difficult Staphylococcus aureus infections: antibodies show the way, Cell Host Microbe, vol.20, pp.555-557, 2016.
URL : https://hal.archives-ouvertes.fr/hal-01398083

Q. Long, B. Liu, H. Deng, G. Wu, K. Deng et al., Antibody responses to SARS-CoV-2 in patients with COVID-19, Nat. Med, 2020.

N. M. Okba, M. A. M?-uller, W. Li, C. Wang, C. H. Geurtsvankessel et al., Severe acute respiratory syndrome coronavirus 2-specific antibody responses in coronavirus disease 2019 patients, Emerg. Infect. Dis, vol.26, 2020.

L. Bao, W. Deng, H. Gao, C. Xiao, J. Liu et al., Reinfection could not occur in SARS-CoV-2 infected rhesus macaques, 2020.

J. Mair-jenkins, M. Saavedra-campos, J. K. Baillie, P. Cleary, F. Khaw et al., The effectiveness of convalescent plasma and hyperimmune immunoglobulin for the treatment of severe acute respiratory infections of viral etiology: a systematic review and exploratory meta-analysis, Convalescent Plasma Study Group, vol.211, pp.80-90, 2015.

J. Ko, H. Seok, S. Y. Cho, Y. E. Ha, J. Y. Baek et al., Challenges of convalescent plasma infusion therapy in Middle East respiratory coronavirus infection: a single centre experience, Antivir. Ther. (Lond.), vol.23, pp.617-622, 2018.

T. C. Luke, E. M. Kilbane, J. L. Jackson, and S. L. Hoffman, Metaanalysis: convalescent blood products for Spanish influenza pneumonia: a future H5N1 treatment?, Ann. Intern. Med, vol.145, pp.599-609, 2006.

I. F. Hung, K. K. To, C. Lee, K. Lee, W. Yan et al., Hyperimmune IV immunoglobulin treatment: a multicenter double-blind randomized controlled trial for patients with severe 2009 influenza A(H1N1) infection, Chest, vol.144, pp.464-473, 2013.

S. Jiang, C. Hillyer, and L. Du, Neutralizing antibodies against SARS-CoV-2 and other human coronaviruses, Trends Immunol, vol.41, pp.355-359, 2020.

J. Sui, W. Li, A. Murakami, A. Tamin, L. J. Matthews et al., Potent neutralization of severe acute respiratory syndrome (SARS) coronavirus by a human mAb to S1 protein that blocks receptor association, Proc. Natl. Acad. Sci. USA, vol.101, pp.2536-2541, 2004.

J. Ter-meulen, E. N. Van-den-brink, L. L. Poon, W. E. Marissen, C. S. Leung et al., Human monoclonal antibody combination against SARS coronavirus: synergy and coverage of escape mutants, PLoS Med, vol.3, p.237, 2006.

X. Chen, R. Li, Z. Pan, C. Qian, Y. Yang et al., Human monoclonal antibodies block the binding of SARS-CoV-2 spike protein to angiotensin converting enzyme 2 receptor, Cell Mol Immunol, 2020.

M. Yuan, N. C. Wu, X. Zhu, C. D. Lee, R. T. So et al., A highly conserved cryptic epitope in the receptorbinding domains of SARS-CoV-2 and SARS-CoV, Science, vol.368, pp.630-633, 2020.

C. Wang, W. Li, D. Drabek, N. M. Okba, R. Van-haperen et al., A human monoclonal antibody blocking SARS-CoV-2 infection, Nat Commun, vol.11, p.2251, 2020.

J. Zhao, Q. Yuan, H. Wang, W. Liu, X. Liao et al., Antibody responses to SARS-CoV-2 in patients of novel coronavirus disease 2019, Clin. Infect. Dis.ciaa344, 2020.

L. Guo, L. Ren, S. Yang, M. Xiao, D. Chang et al., Profiling early humoral response to diagnose novel coronavirus disease (COVID-19), Clin. Infect. Dis.ciaa310, 2020.

. Xinhua, China puts 245 COVID-19 patients on convalescent plasma therapy, 2020.

C. Shen, Z. Wang, F. Zhao, Y. Yang, J. Li et al., Treatment of 5 critically ill patients with COVID-19 with convalescent plasma, JAMA, vol.323, pp.1582-1589, 2020.

K. Duan, B. Liu, C. Li, H. Zhang, T. Yu et al., Effectiveness of convalescent plasma therapy in severe COVID-19 patients, Proc. Natl. Acad. Sci. USA, vol.117, pp.9490-9496, 2020.

. Takeda, Takeda initiates development of a plasma-derived therapy for COVID-19, 2020.

. Grifols, Grifols announces formal collaboration with US government to produce the first treatment specifically targeting COVID-19, 2020.

H. Bian, Z. Zheng, D. Wei, Z. Zhang, W. Kang et al., Meplazumab treats COVID-19 pneumonia: an open-labelled, concurrent controlled add-on clinical trial, 2020.

J. B. Wing, A. Tanaka, and S. Sakaguchi, Human FOXP3 + regulatory T cell heterogeneity and function in autoimmunity and cancer, Immunity, vol.50, pp.302-316, 2019.

E. Stephen-victor, I. Bosschem, F. Haesebrouck, and J. Bayry, The yin and yang of regulatory T cells in infectious diseases and avenues to target them, Cell. Microbiol, vol.19, 2017.
URL : https://hal.archives-ouvertes.fr/hal-01510317

K. E. Webster, S. Walters, R. E. Kohler, T. Mrkvan, O. Boyman et al., In vivo expansion of T reg cells with IL-2-mAb complexes: induction of resistance to EAE and long-term acceptance of islet allografts without immunosuppression, J. Exp. Med, vol.206, pp.751-760, 2009.

E. Trotta, P. H. Bessette, S. L. Silveria, L. K. Ely, K. M. Jude et al., A human anti-IL-2 antibody that potentiates regulatory T cells by a structure-based mechanism, Nat. Med, vol.24, pp.1005-1014, 2018.

A. K. Abbas, E. Trotta, D. Simeonov, A. Marson, and J. A. Bluestone, Revisiting IL-2: biology and therapeutic prospects, Sci. Immunol, vol.3, p.1482, 2018.

M. D. Rosenblum, I. K. Gratz, J. S. Paw, and A. K. Abbas, Treating human autoimmunity: current practice and future prospects, Sci. Transl. Med, vol.4, pp.125-126, 2012.

H. Slater, FDA accepts IND for NK cell therapy CYNK-001 to treat patients with COVID-19, 2020.

M. Million, J. Lagier, P. Gautret, P. Colson, P. Fournier et al., Early treatment of COVID-19 patients with hydroxychloroquine and azithromycin: A retrospective analysis of 1061 cases in Marseille, France, Travel Med Infect, 2020.

Z. Chen, J. Hu, Z. Zhang, S. Jiang, S. Han et al., Efficacy of hydroxychloroquine in patients with COVID-19: results of a randomized clinical trial, 2020.

M. Wang, R. Cao, L. Zhang, X. Yang, J. Liu et al., Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro, Cell Res, vol.30, pp.269-271, 2020.

J. Liu, R. Cao, M. Xu, X. Wang, H. Zhang et al., Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro, Cell Discov, vol.6, p.16, 2020.

M. Mahevas, V. Tran, M. Roumier, A. Chabrol, R. Paule et al., No evidence of clinical efficacy of hydroxychloroquine in patients hospitalized for COVID-19 infection with oxygen requirement: results of a study using routinely collected data to emulate a target trial, 2020.

J. M. Molina, C. Delaugerre, J. Le-goff, B. Mela-lima, D. Ponscarme et al., No evidence of rapid antiviral clearance or clinical benefit with the combination of hydroxychloroquine and azithromycin in patients with severe COVID-19 infection, Med. Mal. Infect, 2020.

J. Geleris, Y. Sun, J. Platt, J. Zucker, M. Baldwin et al., Observational study of hydroxychloroquine in hospitalized patients with Covid-19, N. Engl. J. Med, 2020.